No Data
J.P. Morgan Sticks to Their Buy Rating for Springworks Therapeutics (SWTX)
SpringWorks Therapeutics Initiated at Outperform by Evercore ISI Group
SpringWorks Therapeutics Analyst Ratings
Evercore Initiates SpringWorks Therapeutics(SWTX.US) With Buy Rating, Announces Target Price $60
Express News | SpringWorks Therapeutics Inc : JP Morgan Raises Target Price to $70 From $68
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas